The Liver Meeting 2020-Cholestatic and Autoimmune Liver Diseases SIG New Frontiers in PSC

Video Transcription

Video Summary

The Cholestasis and Autoimmune Liver Diseases Special Interest Group discussed the challenges in treating diseases like primary sclerosing cholangitis and highlighted the potential of fecal microbiota transplantation for manipulation of the gut microbiome. Presenters covered topics such as cholangiocarcinoma, pediatric PSC, autoimmune cholangiopathies, and immune cholangiopathies, emphasizing the importance of understanding the role of cholangiocytes in liver immunity and repair processes. Autoimmune liver disease and primary sclerosing cholangitis have distinct histological and biochemical features, with different treatment approaches including supportive care, medications like ursodeoxycholic acid and immunosuppressants, and possibly liver transplantation. Research is ongoing in children with autoimmune liver disease, with evolving pharmacological management strategies and promising trials on new drugs. Advanced imaging technologies like MRE, MRCP, radiomics, and AI show potential for enhancing diagnostic accuracy, risk assessment, and personalized treatment plans for patients with PSC. The future of imaging in PSC looks promising for improving patient outcomes and clinical decision-making.

Keywords

Cholestasis

Autoimmune liver diseases

Primary sclerosing cholangitis

Fecal microbiota transplantation

Gut microbiome manipulation

Cholangiocarcinoma

Pediatric PSC

Autoimmune cholangiopathies

Immune cholangiopathies

Cholangiocytes

Liver immunity

Ursodeoxycholic acid